Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Mithramycin oral squamous cell carcinoma not applicable detail...
Unknown unknown Temsirolimus oral squamous cell carcinoma not applicable detail...
Unknown unknown TAE226 oral squamous cell carcinoma not applicable detail...
Unknown unknown Everolimus oral squamous cell carcinoma not applicable detail...
Unknown unknown Olaparib + Cisplatin oral squamous cell carcinoma not applicable detail...
Unknown unknown Trametinib oral squamous cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00904345 Phase II Cetuximab Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) Active, not recruiting
NCT01195922 Phase Ib/II Sirolimus Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Completed
NCT01553851 Phase II Trametinib GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Completed
NCT01612351 Phase II Lapatinib + Carboplatin + Cisplatin + Paclitaxel Lapatinib + Carboplatin + Paclitaxel Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Active, not recruiting
NCT01732640 Phase Ib/II Afatinib + Carboplatin + Paclitaxel Cisplatin A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. Terminated
NCT01783587 Phase I Afatinib Docetaxel Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer Active, not recruiting
NCT01810913 Phase II Docetaxel Cisplatin Docetaxel + Cetuximab Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting
NCT01824823 Phase II Afatinib Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence Active, not recruiting
NCT01914900 Phase II Cisplatin + Docetaxel + Fluorouracil Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Unknown status
NCT01927744 Phase II Erlotinib + Docetaxel Cisplatin Docetaxel Carboplatin Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection Active, not recruiting
NCT02196168 Phase II Adavosertib Cisplatin Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated
NCT02289209 Phase II Pembrolizumab Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Recruiting
NCT02296684 Phase II Pembrolizumab Cisplatin Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Recruiting
NCT02334319 Phase I Ganetespib Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Active, not recruiting
NCT02381535 Phase I Cisplatin AT13387 Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin Active, not recruiting
NCT02454179 Phase II Pembrolizumab Acalabrutinib Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma Unknown status
NCT02473731 Phase I CDX-3379 A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Completed
NCT02499120 Phase II Palbociclib Cetuximab Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer Active, not recruiting
NCT02499328 Phase Ib/II AZD9150 + Durvalumab AZD5069 + MEDI4736 Durvalumab AZD9150 Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Recruiting
NCT02551159 Phase III Cisplatin Durvalumab Cetuximab + Carboplatin + Fluorouracil Tremelimumab Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN Active, not recruiting
NCT02585973 Phase I MK-1775 + Cisplatin Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC Recruiting
NCT02586207 Phase I Cisplatin + Pembrolizumab Pembrolizumab in Combination With CRT for LA-SCCHN Active, not recruiting
NCT02741570 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Nivolumab + Ipilimumab Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting
NCT02764593 Phase I Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma Active, not recruiting
NCT02769520 Phase II Pembrolizumab Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Recruiting
NCT02775812 Phase I Cisplatin + Pembrolizumab Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting
NCT02777385 Phase II Cisplatin + Pembrolizumab Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Recruiting
NCT02827838 Phase I Durvalumab Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Recruiting
NCT02873819 Phase II MAGE-A3 vaccine Cyclophosphamide + poly ICLC + Sargramostim Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity Recruiting
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Recruiting
NCT02919683 Phase II Nivolumab Nivolumab + Ipilimumab Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Recruiting
NCT02993991 Phase I MEDI4736 + Mocetinostat Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity Withdrawn
NCT03021993 Phase II Nivolumab Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Recruiting
NCT03162731 Phase I Nivolumab + Ipilimumab Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer Recruiting
NCT03238365 Phase I Nivolumab + Tadalafil Nivolumab Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Recruiting
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Recruiting
NCT03258008 Phase II ISA101b + Utomilumab Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Recruiting
NCT03341936 Phase II Lirilumab + Nivolumab Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03342352 Phase III Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) Withdrawn
NCT03342911 Phase II Nivolumab + Carboplatin + Paclitaxel Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Recruiting
NCT03349710 Phase III Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Active, not recruiting
NCT03370276 Phase Ib/II Cetuximab + Nivolumab Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting
NCT03381183 Phase Ib/II Cyclophosphamide + Durvalumab + Tremelimumab IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma Not yet recruiting
NCT03383094 Phase II Pembrolizumab Cisplatin + Radiotherapy Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer Recruiting
NCT03386838 Phase III BMS-986205 + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck Terminated
NCT03515538 Phase II Cisplatin + RRx-001 RRx-001 Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers Recruiting
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Recruiting
NCT03575234 Phase Ib/II Cyclophosphamide + IRX-2 + Nivolumab Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer Not yet recruiting
NCT03575598 Phase I MGCD516 + Nivolumab Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study Recruiting
NCT03618134 Phase Ib/II Durvalumab Durvalumab + Tremelimumab Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Recruiting
NCT03635164 Phase I Durvalumab Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma Recruiting
NCT03719690 Phase II Tipifarnib Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) Not yet recruiting
NCT03818542 Phase I ABBV-927 ABBV-368 ABBV-181 A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma Not yet recruiting
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03829722 Phase II Nivolumab + Carboplatin + Paclitaxel Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer Not yet recruiting